NL-OMON40896已完成不适用
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications. - MMI-0100 SAD study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male or female
- •18 and 55 years of age, inclusive
- •BMI 19.0 and 30.0 kilograms/meter2
- •Non smokers
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior to the start of this study.
研究者
相似试验
已完成
不适用
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orallyNL-OMON48072OP2 Drugs12
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseasesKCT0004026Kyung Dong Pharmaceutical80
进行中（未招募）
不适用
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2007-002912-24-DEBayer HealthCare AG16
进行中（未招募）
1 期
A study to investigate the safety, pharmacodynamics and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjectsCTIS2023-507409-32-00Cybin IRL Limited72
招募中
1 期
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-JPRN-jRCT2080225128-6